Statin therapy may influence the incidence of postoperative atrial fibrillation: What is the evidence?

Texas Heart Institute Journal

Volumn 36, Issue 6, 2009, Pages 521-529

  Saso, Srdjan ^a   Vecht, Joshua A ^a   Rao, Christopher ^a   Protopapas, Aristotle ^a   Ashrafian, Hutan ^a   Leff, Daniel ^a   Darzi, Ara ^a   Athanasiou, Thanos ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Atrial fibrillation drug therapy physiopathology prevention control; Cardiac surgical procedures complications; Data interpretation, statistical; Hydroxymethylglutaryl CoA reductase inhibitors therapeutic use; Meta analysis as topic; Models, statistical; Postoperative complications drug therapy epidemiology prevention control; Randomized controlled trials as topic methods; Risk factors

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CARDIAC PATIENT; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART SURGERY; HUMAN; INCIDENCE; META ANALYSIS; POSTOPERATIVE COMPLICATION; REVIEW; RISK REDUCTION; SURGICAL RISK; SYSTEMATIC REVIEW; THERAPY EFFECT;

AGED; ATRIAL FIBRILLATION; CARDIAC SURGICAL PROCEDURES; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 76149087446     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82 (8A):2N-9N.
2. Creswell LL, Schuessler RB, Rosenbloom M, Cox JL. Hazards of postoperative atrial arrhythmias. Ann Thorac Surg 1993; 56(3):539-49.
3. Lauer MS, Eagle KA, Buckley MJ, DeSanctis RW. Atrial fibrillation following coronary artery bypass surgery. Prog Cardiovasc Dis 1989;31(5):367-78.
4. Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD, et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004;291(14):1720-9.
5. Ferguson TB Jr, Hammill BG, Peterson ED, DeLong ER, Grover FL; STS National Database Committee. A decade of change - risk profiles and outcomes for isolated coronary artery bypass grafting procedures, 1990-1999: a report from the STS National Database Committee and the Duke Clinical Research Institute. Society of Thoracic Surgeons. Ann Thorac Surg 2002;73(2):480-90.
6. Almassi GH, Schowalter T, Nicolosi AC, Aggarwal A, Moritz TE, Henderson WG, et al. Atrial fibrillation after cardiac surgery: a major morbid event? Ann Surg 1997;226(4):501-13.
7. Ommen SR, Odell JA, Stanton MS. Atrial arrhythmias after cardiothoracic surgery [published erratum appears in N Engl J Med 1997;337(3):209]. N Engl J Med 1997;336(20):1429-34.
8. Sanchez-Quinones J, Marin F, Roldan V, Lip GY. The impact of statin use on atrial fibrillation. QJM 2008;101(11):845-61.
9. Aranki SF, Shaw DP, Adams DH, Rizzo RJ, Couper GS, VanderVliet M, et al. Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation 1996;94(3):390-7.
10. Athanasiou T, Aziz O, Mangoush O, Al-Ruzzeh S, Nair S, Malinovski V, et al. Does off-pump coronary artery bypass reduce the incidence of post-operative atrial fibrillation? A question revisited. Eur J Cardiothorac Surg 2004;26(4):701-10.
11. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110(9): 1042-6.
12. Tsang TS, Miyasaka Y, Barnes ME, Gersh BJ. Epidemiological profile of atrial fibrillation: a contemporary perspective. Prog Cardiovasc Dis 2005;48(1):1-8.
13. Schoonderwoerd BA, Smit MD, Pen L, Van Gelder IC. New risk factors for atrial fibrillation: causes of 'not-so-lone atrial fibrillation'. Europace 2008;10(6):668-73.
14. Mayr M, Yusuf S, Weir G, Chung YL, Mayr U, Yin X, et al. Combined metabolomic and proteomic analysis of human atrial fibrillation. J Am Coll Cardiol 2008;51(5):585-94.
15. Jahangiri M, Weir G, Mandal K, Savelieva I, Camm J. Current strategies in the management of atrial fibrillation. Ann Thorac Surg 2006;82(1):357-64.
16. Schoonderwoerd BA, Van Gelder IC, Van Veldhuisen DJ, Van den Berg MP, Crijns HJ. Electrical and structural remodeling: role in the genesis and maintenance of atrial fibrillation. Prog Cardiovasc Dis 2005;48(3):153-68.
17. Peters NS, Schilling RJ, Kanagaratnam P, Markides V. Atrial fibrillation: strategies to control, combat, and cure. Lancet 2002;359(9306):593-603.
18. Savelieva I, Camm J. Update on atrial fibrillation: part I. Clin Cardiol 2008;31(2):55-62.
19. Otway R, Vandenberg JI, Fatkin D. Atrial fibrillation - a new cardiac channelopathy. Heart Lung Circ 2007;16(5):356-60.
20. Adam O, Neuberger HR, Bohm M, Laufs U. Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Circulation 2008;118(12):1285-93.
21. Virani SS, Nambi V, Razavi M, Lee VV, Elayda M, Wilson JM, Ballantyne CM. Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery. Am Heart J 2008;155(3):541-6.
22. Powell BD, Bybee KA, Valeti U, Thomas RJ, Kopecky SL, Mullany CJ, Wright RS. Influence of preoperative lipid-lowering therapy on postoperative outcome in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007;99(6): 785-9.
23. Chello M, Patti G, Candura D, Mastrobuoni S, Di Sciascio G, Agro F, et al. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med 2006;34(3):660-7.
24. Auer J, Weber T, Berent R, Lamm G, Ng CK, Hartl P, et al. Use of HMG-coenzyme a-reductase inhibitors (statins) and risk reduction of atrial fibrillation after cardiac surgery: results of the SPPAF study, a randomised placebo-controlled trial [abstract]. Eur Heart J 2004;25(Suppl):353.
25. Kourliouros A, De Souza A, Roberts N, Marciniak A, Tsiouris A, Valencia O, et al. Dose-related effect of statins on atrial fibrillation after cardiac surgery. Ann Thorac Surg 2008;85(5): 1515-20.
26. Lertsburapa K, White CM, Kluger J, Faheem O, Hammond J, Coleman CI. Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery. J Thorac Cardiovasc Surg 2008;135(2):405-11.
27. Marin F, Pascual DA, Roldan V, Arribas JM, Ahumada M, Tornel PL, et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 2006;97(1):55-60.
28. Mariscalco G, Lorusso R, Klersy C, Ferrarese S, Tozzi M, Vanoli D, et al. Observational study on the beneficial effect of preoperative statins in reducing atrial fibrillation after coronary surgery. Ann Thorac Surg 2007;84(4):1158-64.
29. Ozaydin M, Dogan A, Varol E, Kapan S, Tuzun N, Peker O, et al. Statin use before by-pass surgery decreases the incidence and shortens the duration of postoperative atrial fibrillation. Cardiology 2007;107(2):117-21.
30. Pan W, Pintar T, Anton J, Lee VV, Vaughn WK, Collard CD. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation 2004;110(11 Suppl 1):II45-9.
31. Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E, Sciascio G. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006;114(14):1455-61.
32. Song YB, On YK, Kim JH, Shin DH, Kim JS, Sung J, et al. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery. Am Heart J. 2008 Aug;156(2):373.e9-16.
33. Cochrane Reviewers' Handbook. The Cochrane Collaboration; Issue 3. Oxford (UK): Update Software; 2001.
34. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999;354(9193):1896- 900.
35. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27(5):335-71.
36. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22(4):719-48.
37. Systematic reviews in health care: meta-analysis in context. Egger M, Smith GD, Altman DG, editors. 2nd ed. London: BMJ Publishing Group; 1995.
38. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177-88.
39. Stamou SC, Jablonski KA, Pfister AJ, Hill PC, Dullum MK, Bafi AS, et al. Stroke after conventional versus minimally invasive coronary artery bypass. Ann Thorac Surg 2002;74(2): 394-9.
40. England MR, Gordon G, Salem M, Chernow B. Magnesium administration and dysrhythmias after cardiac surgery. A placebo-controlled, double-blind, randomized trial. JAMA 1992;268(17):2395-402.
41. Thompson SG, Pocock SJ. Can meta-analyses be trusted? Lancet 1991;338(8775):1127-30.
42. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004;62(1):105-11.
43. Shiroshita-Takeshita A, Brundel BJ, Burstein B, Leung TK, Mitamura H, Ogawa S, Nattel S. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res 2007;74(1):75-84.
44. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 2004;110(16):2313-9.
45. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352(1): 29-38.
46. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, Mc-Cabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352(1):20-8.
47. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118.
48. Takahashi N, Ishibashi Y, Shimada T, Sakane T, Ohata S, Sugamori T, et al. Impaired exercise-induced vasodilatation in chronic atrial fibrillation--role of endothelium-derived nitric oxide. Circ J 2002;66(6):583-8.
49. Di Napoli P, Taccardi AA, Grilli A, De Lutiis MA, Barsotti A, Felaco M, De Caterina R. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res 2005;66(3):462-71.
50. Kourliouros A, Roberts N, Jahangiri M. Statins with equivalent lipid-lowering capacity exhibit differential effects on atrial fibrillation after cardiac surgery. J Thorac Cardiovasc Surg 2008;136(4):1100-1.